Anesthesia Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Questions

5-HT₃ receptor antagonists clinical use(s):
1. Nausea following upper abdominal irradiation (e.g. in cancer therapy)
2. Cancer chemotherapy associated nausea.
3. Both
4. Neither
5-HT₃receptor antagonist clinical use(s):
1. Pregnancy hyperemesis
2. Motion sickness
3. Both
4. Neither
Palonosetron, distinct from other 5-HT₃ receptor antagonists, is possibly effective in managing delayed emesis.
1. True
2. False
The combination of palonosetron and netupitant (Akynzeo, a neurokinin blocker):
1. Useful in managing acute nausea and vomiting.
2. Useful in managing delayed nausea and vomiting.
3. Both
4. Neither
Adding dexamethasone, a corticosteroid, to the combination of palonosetron and natupitant is considered a highly effective three-drug combination.
1. True
2. False
This agent classified primarily as a 5-HT₃ antagonist also exhibits some weak 5-HT₄ blocking properties.
1. Granisetron
2. Palonosetron
3. Ondansetron
4. Dolasetron
Longest half-life:
1. Ondansetron
2. Granisetron
3. Dolasetron
4. Palonosetron
QT prolongation, an electrocardiographic change, is a characteristic of first-generation 5-HT₃ blocking drugs.
1. True
2. False
The 5-HT₃ class of agents has been shown associated with serotonin syndrome and therefore should be used cautiously if patients are taking medications that could increase serotonin levels e.g. serotonin selective reuptake inhibitors (SSRIs).
1. True
2. False
Dolasetron: contraindicated for prophylaxis against chemotherapy-induced nausea and vomiting.
1. True
2. False

Anesthesia Pharmacology: Gastrointestinal Pharmacology Practice Questions